Acute Leukemia, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders
Conditions
Brief summary
The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.
Interventions
PROCEDUREblood draw, bone marrow procedure, or tissue biopsy
Sponsors
OHSU Knight Cancer Institute
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD * Male or female of all ages * Willing and able to sign informed consent * Willing guardian consent for participants under 18 years of age
Exclusion criteria
* No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) | After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care | Integrated functional genomics studies (whole genome sequencing, RNAi, proteomics, drug sensitivity, expression profiling) will be used to identify aberrant signaling pathways that contribute to the formation of hematologic malignancies. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORCristina Tognon, PhD
OHSU Knight Cancer Institute
Outcome results
None listed